Feline mammary carcinoma (FMC) is a common aggressive malignancy with a low survival rate that lacks viable therapeutic options beyond mastectomy. Recently, increasing efforts have been made to understand the molecular mechanisms underlying FMC development, using the knowledge gained from studies on human breast cancer to discover new diagnostic and prognostic biomarkers, thus reinforcing the utility of the cat as a cancer model. In this article, we review the current knowledge on FMC pathogenesis, biomarkers, and prognosis factors and offer new insights into novel therapeutic options for HER2-positive and triple-negative FMC subtypes.
Keywords: biomarkers; comparative oncology model; feline her2 mutations; feline mammary carcinoma; targeted therapies.
Conflict of interest statement
The authors declare no conflict of interest.
VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.Cancers (Basel). 2021 Nov 5;13(21):5559. doi: 10.3390/cancers13215559.PMID: 34771722 Free PMC article.
Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.Oncotarget. 2017 Nov 11;8(62):105775-105789. doi: 10.18632/oncotarget.22398. eCollection 2017 Dec 1.PMID: 29285291 Free PMC article.
HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.Cancers (Basel). 2021 Apr 21;13(9):2007. doi: 10.3390/cancers13092007.PMID: 33919468 Free PMC article.
Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer.BMC Cancer. 2019 Dec 30;19(1):1267. doi: 10.1186/s12885-019-6483-6.PMID: 31888566 Free PMC article.
Prognostic evaluation of feline mammary carcinomas: a review of the literature.Vet Pathol. 2015 Jan;52(1):46-60. doi: 10.1177/0300985814528221. Epub 2014 Apr 16.PMID: 24741029 Review.